Related Experiment Video

Updated: Aug 17, 2026

Temporal Tracking of Cell Cycle Progression Using Flow Cytometry without the Need for Synchronization
08:52

Temporal Tracking of Cell Cycle Progression Using Flow Cytometry without the Need for Synchronization

Published on: August 16, 2015

Sensitization of cancer cells to DNA damage-induced cell death by specific cell cycle G2 checkpoint abrogation

M Suganuma1, T Kawabe, H Hori

  • 1Department of Molecular Genetics, Nagoya City University School of Medicine, Nagoya, Japan.

Cancer Research
|December 22, 1999
PubMed

Insights

New peptides targeting the G2 checkpoint inhibit human checkpoint kinase 1 (hChk1) and Chk2/HuCds1 activity. This cancer therapy strategy sensitizes cancer cells to DNA-damaging agents, sparing normal cells.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Cancer Research

Background:

  • The G2 checkpoint is crucial for cell cycle regulation and DNA repair.
  • Dysregulation of the G2 checkpoint is implicated in cancer development.
  • Human checkpoint kinase 1 (hChk1) and Chk2/HuCds1 are key regulators of the G2 checkpoint.

Purpose of the Study:

  • To develop novel peptides that specifically target and inhibit hChk1 and Chk2/HuCds1.
  • To evaluate the therapeutic potential of these peptides in abrogating the G2 checkpoint in cancer cells.
  • To assess the efficacy of G2 checkpoint abrogation in sensitizing cancer cells to DNA-damaging agents.

Main Methods:

  • Design and synthesis of peptides based on Cdc25C and HIV-1 TAT.
  • In vitro kinase assays to measure hChk1 and Chk2/HuCds1 inhibition.
  • In vivo studies to assess G2 checkpoint abrogation and cell viability in cancer and normal cells.

Main Results:

  • The synthesized peptides effectively inhibited hChk1 and Chk2/HuCds1 kinase activity in vitro.
  • These peptides specifically abrogated the G2 checkpoint in vivo.
  • Peptides sensitized p53-defective cancer cell lines to DNA-damaging agents, leading to cell death.
  • No significant cytotoxic effects were observed in normal cells.

Conclusions:

  • Specific abrogation of the cell cycle G2 checkpoint is a viable strategy for cancer therapy.
  • hChk1 and Chk2/HuCds1 are appropriate therapeutic targets for G2 checkpoint abrogation.
  • The developed peptides show promise as novel anti-cancer agents.

More Related Videos

Studying Cell Cycle-regulated Gene Expression by Two Complementary Cell Synchronization Protocols12:02

Studying Cell Cycle-regulated Gene Expression by Two Complementary Cell Synchronization Protocols

Published on: June 6, 2017

Cell Cycle-specific Measurement of γH2AX and Apoptosis After Genotoxic Stress by Flow Cytometry08:21

Cell Cycle-specific Measurement of γH2AX and Apoptosis After Genotoxic Stress by Flow Cytometry

Published on: September 1, 2019

Related Concept Videos

Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
The Cell Cycle Control System01:28

The Cell Cycle Control System

The cell cycle regulation directs how a cell proceeds from one phase to the next and begins mitosis. The cell cycle control system includes intracellular regulatory molecules and external triggers. They provide "stop" or "advance" signals and operate at specific cell cycle stages termed checkpoints to ensure that a particular process is completed before the cell advances to the next phase.
Cyclins and cyclin-dependent kinases (Cdks) are the primary cell cycle regulators and function at the cell...